Long-term costs of introducing HPV-DNA post-treatment surveillance to national cervical cancer screening in Ireland.
Expert Rev Pharmacoecon Outcomes Res
; 15(6): 999-1005, 2015.
Article
em En
| MEDLINE
| ID: mdl-26377838
ABSTRACT
INTRODUCTION:
Co-testing (cytology plus human papillomavirus DNA testing) as part of cervical cancer surveillance in Ireland increases one-time testing costs. Of interest to policy makers was the long-term impact of these costs accompanied by decreases in intensity of recalls for women with no detected abnormalities.METHODS:
A cost analysis of cytology-only and co-testing strategy was implemented using decision analytic modeling, aggregating testing utilization and costs for each of the two strategies over 12 years.RESULTS:
Aggregated incremental costs of the co-testing strategy were positive for the first 3 years but became negative thereafter, generating a cost savings of roughly 20 million in favor of the cytology-only strategy over a 12-year period. Results were robust over a range of sensitivity analyses with respect to discount and attrition rates.DISCUSSION:
This analysis provided valuable information to policy makers contributing to the introduction of co-testing for post-treatment surveillance (PTS) in Ireland.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
DNA Viral
/
Neoplasias do Colo do Útero
/
Programas de Rastreamento
/
Infecções por Papillomavirus
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article